Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8724971 | 0.81 | KCNH2 (0.58) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL24811923 | 0.81 | KCNH2 (0.53) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL8849490 | 0.81 | KCNH2 (0.49) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL16770391 | 0.79 | KCNH2 (0.55) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL31573982 | 0.78 | KCNH2 (0.67) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL25590542 | 0.77 | KCNH2 (0.53) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL23015030 | 0.77 | KCNH2 (0.53) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL1789855 | 0.77 | LMNA (0.50) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL2140584 | 0.77 | KCNH2 (0.45) | KCNH2SIGMAR1MITFLMNAESRRG | |
| SCHEMBL793588 | 0.77 | KCNH2 (0.50) | KCNH2SIGMAR1MITFLMNAESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | KCNH2 4046/4885SIGMAR1 2897/4885MITF 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.